Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models

Even after development of the JAK1/JAK2 inhibitor ruxolitinib, myeloproliferative neoplasm (MPN) patients require novel therapeutic options. While ruxolitinib can considerably improve quality of life and prolong survival, it does not modify the natural disease course in most patients. Moreover, resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Basu, Titiksha, Bertrand, Hannah, Karantzelis, Nikolaos, Gründer, Albert, Pahl, Heike L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092367/
https://www.ncbi.nlm.nih.gov/pubmed/33954282
http://dx.doi.org/10.1097/HS9.0000000000000565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092367/
https://www.ncbi.nlm.nih.gov/pubmed/33954282
http://dx.doi.org/10.1097/HS9.0000000000000565

Ejemplares similares